- Home
- CRVS vs AMBC Comparison
CRVS vs AMBC Comparison
Compare CRVS & AMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- AMBC
- Stock Information
- Founded
- CRVS 2014
- AMBC 1971
- Country
- CRVS United States
- AMBC United States
- Employees
- CRVS N/A
- AMBC N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- AMBC Property-Casualty Insurers
- Sector
- CRVS Health Care
- AMBC Finance
- Exchange
- CRVS Nasdaq
- AMBC Nasdaq
- Market Cap
- CRVS 459.0M
- AMBC 411.3M
- IPO Year
- CRVS 2016
- AMBC 1991
- Fundamental
- Price
- CRVS $5.79
- AMBC $8.96
- Analyst Decision
- CRVS Strong Buy
- AMBC Strong Buy
- Analyst Count
- CRVS 4
- AMBC 2
- Target Price
- CRVS $15.00
- AMBC $12.50
- AVG Volume (30 Days)
- CRVS 547.2K
- AMBC 509.7K
- Earning Date
- CRVS 11-11-2025
- AMBC 11-11-2025
- Dividend Yield
- CRVS N/A
- AMBC N/A
- EPS Growth
- CRVS N/A
- AMBC N/A
- EPS
- CRVS N/A
- AMBC N/A
- Revenue
- CRVS N/A
- AMBC $257,879,000.00
- Revenue This Year
- CRVS N/A
- AMBC N/A
- Revenue Next Year
- CRVS N/A
- AMBC $19.44
- P/E Ratio
- CRVS N/A
- AMBC N/A
- Revenue Growth
- CRVS N/A
- AMBC 148.44
- 52 Week Low
- CRVS $2.54
- AMBC $5.99
- 52 Week High
- CRVS $10.00
- AMBC $13.64
- Technical
- Relative Strength Index (RSI)
- CRVS 56.88
- AMBC 57.12
- Support Level
- CRVS $5.64
- AMBC $8.40
- Resistance Level
- CRVS $6.09
- AMBC $9.03
- Average True Range (ATR)
- CRVS 0.34
- AMBC 0.29
- MACD
- CRVS -0.05
- AMBC -0.05
- Stochastic Oscillator
- CRVS 50.00
- AMBC 58.95
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. It operates in two principal businesses segments: Insurance Distribution and Specialty Property & Casualty Insurance. Insurance Distribution segment includes Managing General Agents, Underwriters and other appointed and delegated underwriting businesses (collectively MGAs or MGA/Us), an insurance broker, and other distribution and underwriting businesses. Specialty Property & Casualty Insurance includes five carriers (collectively, Everspan). Key revenue is generated from Insurance Distribution.